Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01912222 · ClinicalTrials.gov registry record · Phase 1
Pharmacokinetic Study of Oral IXAZOMIB in Cancer Patients With Liver Dysfunction
A Phase 1 study, sponsored by Millennium Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 48
- Enrollment target
NCT01912222 is a Phase 1 study that has completed, run by Millennium Pharmaceuticals. The registered enrollment target is 48 participants.
The verdict
NCT01912222, a Phase 1 study, has completed, sponsored by Millennium Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 48 participants
- Enrollment target
Study Summary
This is a phase 1, 2-part, pharmacokinetic study in patients with advanced solid tumors or hematologic malignancies and varying degrees of liver dysfunction (normal function, moderate hepatic impairement or severe hepatic impairment) as defined by the National Cancer Institute (NCI) Organ Dysfunction Working Group.
Interventions
- DRUG IXAZOMIB
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 48 participants |
| Start Date | 2013-08 |
| Est. Completion | 2015-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01912222
The ClinicalTrials.gov registry entry for NCT01912222 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 48 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Millennium Pharmaceuticals, which has 135 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which IXAZOMIB is the first listed.
NCT01912222 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01912222 about?
NCT01912222 is a clinical study titled "Pharmacokinetic Study of Oral IXAZOMIB in Cancer Patients With Liver Dysfunction". This is a phase 1, 2-part, pharmacokinetic study in patients with advanced solid tumors or hematologic malignancies and varying degrees of liver dysfunction (normal function, moderate hepatic impairement or severe hepatic impairment) as defined by the National Cancer Institute (NCI) Organ Dysfunctio...
What is the current status of trial NCT01912222?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 48 participants. The study started on 2013-08. Estimated completion is 2015-03.
What interventions are being tested in trial NCT01912222?
The interventions under investigation include: IXAZOMIB (DRUG).
Who is sponsoring clinical trial NCT01912222?
This trial is sponsored by Millennium Pharmaceuticals, which has 135 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.